Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

9 questions · 9 findings · 1 reviews · Schizophrenia

No studies found 3 · 33.3%GRADE not reported 0 · 0%Very low 1 · 11.1%Low 3 · 33.3%Moderate 2 · 22.2%High 0 · 0%

ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS vs placebo

Tardive dyskinesia: No clinically important improvement · female and male 59‐80 (mean) years old patients with antipsychotic‐induced tardive dyskinesia

ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS may leads to lower tardive dyskinesia: No clinically important improvement compared with PLACEBO (low certainty).

1 finding from 1 review

Buspirone vs placebo

Tardive dyskinesia: No clinically important improvement · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia

ANXIOLYTIC ‐ BUSPIRONE may leads to lower tardive dyskinesia: No clinically important improvement compared with PLACEBO (low certainty).

1 finding from 1 review

Ginkgo biloba vs placebo

Tardive dyskinesia: No clinically important improvement · male 45.2 (mean) years old patients with schizophrenia and antipsychotic‐induced tardive dyskinesia

HERB ‐ GINKGO BILOBA probably leads to lower tardive dyskinesia: No clinically important improvement compared with PLACEBO (moderate certainty).

1 finding from 1 review

HYPNOSIS or RELAXATION vs TAU

Tardive dyskinesia: No clinically important improvement · female and male 35 (mean) years old patients with schizophrenia and tardive dyskinesia, acute extrapyramidal symptoms, and/or…

It is very uncertain whether HYPNOSIS or RELAXATION changes tardive dyskinesia: No clinically important improvement compared with TAU (very low certainty).

1 finding from 1 review

ENZYME INHIBITOR ‐ VMAT2‐INHIBITOR (valbenazine) vs placebo

Tardive dyskinesia: No clinically important improvement · 18 to 85 year‐old patients with schizophrenia, schizoaffective disorder, mood disorder, or gastrointestinal disorder +…

ENZYME INHIBITOR ‐ VMAT2‐INHIBITOR (valbenazine) probably leads to lower tardive dyskinesia: 1. No clinically important improvement compared with PLACEBO (moderate certainty).

1 finding from 1 review